FDA offers updated guidance for generics of weight loss blockbusters
The FDA revised its draft guidance for generic companies looking to develop copycats of some of the world's best-selling weight loss drugs, including Eli Lilly's Zepbound and Novo Nordisk's Ozempic. The updates disclosed Tuesday may ...
read at Endpoints ↗RegulatoryNeutral
July 28, 2026 02:08 PM EDT FDA+GLP-1 drugs FDA offers updated guidance for generics of weight loss blockbusters Zachary Brennan Senior Editor The FDA revised its draft guidance for generic companies looking to develop copycats of some of the world’s best-selling weight loss drugs, including Eli Lilly’s … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that